A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Latest Information Update: 09 Aug 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Facial wrinkles; Glabellar lines
- Focus Therapeutic Use
- Acronyms ULTRA II
- Sponsors Merz Pharmaceuticals GmbH
- 25 Jul 2022 Status changed from active, no longer recruiting to completed.
- 20 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 06 Apr 2021 Planned End Date changed from 1 Jun 2022 to 1 Aug 2022.